Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Slides:

Advertisements

Similar presentations

Figure 1 Diagram showing analysis flow of patient selection and treatment allocation of ONTARGET/TRANSCEND. Figure 1 Diagram showing analysis flow of patient.

Advertisements

Figure 1 Rates of complications and mortality during index admission for atrial fibrillation ablation for the overall ... Figure 1 Rates of complications.

Figure 1 Periprocedural myonecrosis and myocardial infarction after left main coronary artery revascularization with ... Figure 1 Periprocedural myonecrosis.

Figure 1 Subject phenotypes and most common genotype in subjects enrolled in THAOS in continental Western Europe. Data ... Figure 1 Subject phenotypes.

Figure 1 Study flow diagram and definition of clinical response

Figure 1 Overall lag-cumulative exposure–response relationships between air temperature and myocardial infarction ... Figure 1 Overall lag-cumulative exposure–response.

Unless provided in the caption above, the following copyright applies to the content of this slide: © 2019 European Society of Cardiology and British Pharmacological.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.

Figure 1 Data-selection process

Figure 1 Flow diagram detailing the systematic review process.

Figure 1 Multivariable-adjusted predictors of PAC

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

(A) Mean (s.d.) ... (A) Mean (s.d.) baseline values for study variables for patients with and without tophi. (B) Baseline (s.d.) quality of life scores.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Figure 1 Unadjusted Kaplan–Meier curves for all-cause mortality in the transcatheter mitral valve repair and ... Figure 1 Unadjusted Kaplan–Meier curves.

Figure 1 Mechanism of mortality benefit associated with radial access

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Figure 1 Number of percutaneous coronary interventions (PCI) in mainland China, 2017 (total 753 142). Data from China ... Figure 1 Number of percutaneous.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.

Figure 1 The Kaplan–Meier curves of time to death post first hospitalization. hosp, hospitalization. Unless provided in the caption above, the following.

AHA: American Heart Association; ALT: ...

Figure 1. Serum ceftazidime concentrations following intravenous administration. Unless provided in the caption above, the following copyright applies.

Figure 1 A dot plot illustrating the correlation between the yearly absolute risk difference for both MACE and major ... Figure 1 A dot plot illustrating.

Figure 1 Comparison of MITRA-FR and COAPT trial outcomes

Source: Figure created by the author based on data ...

bDMARD: biologic DMARD.

Black: diagnosis ... Black: diagnosis from any department; grey: diagnosis at a rheumatology department. Unless provided in the caption above, the following.

RCTs: randomized controlled ...

Fig. 1 MRI aspect of an osteitis of the left acetabulum at baseline (A), 3 months (B), 1 year (C) and 2 years later, ... Fig. 1 MRI aspect of an osteitis.

Take home figure The protective role of CNP/NPR-B/NPRC.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.

Take home figure The 38% of heart failure reduced ejection fraction (HFrEF) patients who recovered LVEF (HFrecEF) were more ... Take home figure The 38%

Fig. 1. A flowchart of cohort participants screened, enrolled and followed-up between 1 July 2015 and 31 May Fig. 1. A flowchart of cohort participants.

Fig. 1 Subacute cutaneous lupus erythematous at the lower limbs

Fig. 1 Flow chart of included patients for analyses

Fig. 1 Flow chart for selection of study subjects

Figure 1. Survival curves from a hypothesized clinical trial randomizing patient to standard of care with and without ... Figure 1. Survival curves from.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Figure 1 Selection algorithm of patients being included in the German Aortic Valve Registry in 2014 and Figure 1 Selection algorithm of patients.

Figure 1 Cumulative late adjusted survival in cardiac resynchronization therapy defibrillator and pacemaker patients. ... Figure 1 Cumulative late adjusted.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Figure 1 Immunohistochemistry for human cell differentiation molecules in samples of the right ventricular septum from ... Figure 1 Immunohistochemistry.

Figure 1. Results of search based on the PRISMA statement.14

Figure 1. Percentage of Pacific and European children completing all components of B4SC in 2013 and 2015 Figure 1. Percentage of Pacific and European.

Figure Ranking of Cardiovascular Journals as published by Clarivate Analytics. Unless provided in the caption above, the following copyright applies.

Figure 1. Trunk and leg fat over study period. LS, log transformed.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Take home figure Proposed mechanisms of Staphylococcus aureus endocarditis. CVC, central venous catheter; IV, intravenous; S. ... Take home figure Proposed.

Fig. 1 Kaplan-Meier plot presenting no difference in progression to RA in patients with clinically suspect ... Fig. 1 Kaplan-Meier plot presenting no difference.

Figure 1. Oncoprint of selected pathogenic alterations detected in ctDNA. Unless provided in the caption above, the following copyright applies to the.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published by Oxford University Press on behalf of the.

Figure 1 Patient selection

Figure 1 Design of trials included in individual patient data meta-analysis. Unless provided in the caption above, the following copyright applies to the.

Fig. 1 A network representation of top 100 co-occurring terms

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Figure 1 Patient selection.

The figure shows the fraction of ...

Figure 1 Grant agencies and charitable foundations supporting Plan S.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology.

Figure 1 The picture shows the three different procedures, all performed through transseptal access and using an ... Figure 1 The picture shows the three.

Figure 2. Forest plot of multivariable Cox proportional hazard regression illustrating the impact of chemoradiation ... Figure 2. Forest plot of multivariable.

Figure 1. Kaplan Meier curves showing crude product limit survival estimates and 95% confidence intervals for time to ... Figure 1. Kaplan Meier curves.

Figure 1 ABCDE of primary prevention.2

Figure 1. Forest plot of lung cancer mortality in LDCT trials.

Figure 1. Evolutionary process of a policy field.

Figure 1. Overall response rates in wild-type versus RAS and RAS/BRAF mutations detected by nanofluidic digital PCR ... Figure 1. Overall response rates.

Presentation transcript:

Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2018. For permissions, please email: journals.permissions@oup.com.This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model) Eur Heart J, Volume 39, Issue 45, 26 August 2018, Pages 3999–4008, https://doi.org/10.1093/eurheartj/ehy555 The content of this slide may be subject to copyright: please see the slide notes for details.

Figure 1 Trial flowchart. Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2018. For permissions, please email: journals.permissions@oup.com.This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model) Eur Heart J, Volume 39, Issue 45, 26 August 2018, Pages 3999–4008, https://doi.org/10.1093/eurheartj/ehy555 The content of this slide may be subject to copyright: please see the slide notes for details.

Take home figure The Kaplan–Meier curves comparing cumulative incidence of the primary and secondary endpoints in the two ... Take home figure The Kaplan–Meier curves comparing cumulative incidence of the primary and secondary endpoints in the two study groups. (A) The cumulative incidence of the primary composite outcome of death due to heart failure, or hospitalization due to heart failure, or worsening heart failure is shown. (B) The cumulative incidence of patients who died from heart failure or were hospitalized for heart failure is shown. (C) The cumulative incidence of patients who died from any cause is shown. The event rates at one at 2 years of follow-up are shown (D) The cumulative incidence of patients who were hospitalized for heart failure is shown.. Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2018. For permissions, please email: journals.permissions@oup.com.This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model) Eur Heart J, Volume 39, Issue 45, 26 August 2018, Pages 3999–4008, https://doi.org/10.1093/eurheartj/ehy555 The content of this slide may be subject to copyright: please see the slide notes for details.

Figure 2 Subgroup analyses of the primary endpoint Figure 2 Subgroup analyses of the primary endpoint. Hazard ratio and P values for interaction are based on Cox ... Figure 2 Subgroup analyses of the primary endpoint. Hazard ratio and P values for interaction are based on Cox logistic-regression analyses. There was a significant interaction of the primary endpoint (death from heart failure, or hospitalization for heart failure, or worsening heart failure) with ejection fraction and Specific Symptom Scale, which implies that patients with an ejection fraction ≤35% and those with more symptomatic atrial fibrillation (Specific Symptom Scale >31) are more likely to benefit from AV junction ablation and cardiac resynchronization therapy pacing. Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2018. For permissions, please email: journals.permissions@oup.com.This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model) Eur Heart J, Volume 39, Issue 45, 26 August 2018, Pages 3999–4008, https://doi.org/10.1093/eurheartj/ehy555 The content of this slide may be subject to copyright: please see the slide notes for details.

Figure 3 Symptoms and physical limitations assessed by Specific Symptom Scale score, at the baseline and at 1 year ... Figure 3 Symptoms and physical limitations assessed by Specific Symptom Scale score, at the baseline and at 1 year follow-up visit. On-treatment analysis in patients with ejection fraction ≤35% and in those with ejection fraction >35%. Mean values and 95% confidence interval are reported. EF, ejection fraction; SSS, specific symptom scale. Unless provided in the caption above, the following copyright applies to the content of this slide: Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2018. For permissions, please email: journals.permissions@oup.com.This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model) Eur Heart J, Volume 39, Issue 45, 26 August 2018, Pages 3999–4008, https://doi.org/10.1093/eurheartj/ehy555 The content of this slide may be subject to copyright: please see the slide notes for details.